Bellen Chemistry Further Validates its R&D Facilities by Participating in VERIF.i®, Scientist.com’s Supplier Pre-assessment Program
Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that VERIF.i®, the company’s supplier pre-assessment program, has been used to conduct an onsite assessment of Bellen Chemistry’s facility in Shandong, China, which opened in 2017. Scientist.com developed VERIF.i to help its marketplace service providers showcase capabilities to their customers while improving quality standards internally.
Bellen Chemistry is a leading contract research organization (CRO)/contract development and manufacturing organization (CDMO) committed to providing chemical synthesis for small molecule compounds in new drug development, from initial lead compound screening and optimization to preclinical and clinical studies. Bellen has created a one-stop-shop chemistry and chemical manufacturing service platform ranging from compound selection to final API GMP manufacturing.
“With more than 1,000 R&D projects and over 3,000 innovative new molecules being completed each year at our facilities, Bellen places the utmost importance on the quality of our operational processes and the dedicated frontline staff carrying them out,” stated Bob Liu, PhD, Co-founder & CEO of Bellen Chemistry. “By showcasing our compliance with international standard management processes and strict oversight of production processes, VERIF.i allows us to demonstrate our commitment to quality across the biopharma industry in North America, Europe and Japan.”
VERIF.i provides suppliers of regulated research services, including human biospecimen acquisition, animal welfare and chemistry, manufacturing, and controls (CMC), the platform to proactively communicate their standards against established criteria developed specifically for the biopharma industry through onsite pre-assessments. The pre-assessments are conducted by independent, third-party auditors to maintain the integrity of the site visit. Pre-assessments help suppliers such as Bellen Chemistry demonstrate their quality and capabilities, while also helping pharma and biotech customers purchase regulated services in an accelerated manner with more confidence and less risk.
“When sourcing regulated services that inherently have high reputational risk, resource-intensive onsite pre-assessments of partner laboratories become an essential part of the due diligence process,” stated Matt McLoughlin, SVP of Categories and Compliance at Scientist.com. “By creating a standardized process set against pre-defined criteria, VERIF.i addresses this barrier for both customers and suppliers, saving time and money. The program also enables suppliers like Bellen to differentiate themselves from their peers by sharing independent insight into their facilities, personnel and processes.”
VERIF.i is an expansion of Scientist.com’s award-winning COMPLi® solution. For more information visit https://www.scientist.com/verifi/.
About Bellen Chemistry
Bellen Chemistry has been providing chemistry CRO/CDMO services as an integrated Contract Chemistry Service Organization since 2010. With years of accumulated technical advantages and experience in chemical synthesis of small molecule compounds, Bellen has built a one-stop-shop chemistry service platform, supporting big pharmas, biotech innovators and new drug development institutions for their research programs from discovery to commercial stage through comprehensive chemistry solutions.
Our R&D, production, sales and operation team are based globally and at present, Bellen has nearly 1,000 employees worldwide, of which our technical team accounts for around 50%.
About Scientist.com
Scientist.com is a privately held, San Diego-based company on a mission to make it faster and cheaper to discover new medicines. At its heart is an AI-powered marketplace for complex custom experiments that helps drug researchers use innovative technologies to rapidly translate their ideas into actionable data. Through Scientist.com, scientists communicate directly with research experts at over 4,000 global laboratories to design and execute complex research experiments.
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231003352825/en/
Contact information
Media Contact:
Sean Preci
+1 858 771-3813
marketing@scientist.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Coca-Cola Company Names New Leader for Europe Operating Unit18.7.2025 22:00:00 EEST | Press release
The Coca-Cola Company today announced that Luisa Ortega will become president of the Europe operating unit effective Sept. 1, succeeding Nikos Koumettis, who will retire in 2026 after a 25-year career with the company. Koumettis will remain with the company through Feb. 28, 2026, as a senior advisor. He will also serve on the board of directors of Hindustan Coca-Cola Beverages Pvt. Ltd., a company-owned bottler in India. Ortega joined Coca-Cola in 2019 and currently serves as president of the Africa operating unit. In this role, she leads a complex business that operates across 54 markets. Koumettis has led the Europe operating unit since it was created in 2021. “Luisa has done an outstanding job leading our African business, where our system has continued to make major investments to serve growing markets on the continent,” said Henrique Braun, Executive Vice President and Chief Operating Officer of The Coca-Cola Company. “As head of Europe, she will bring great international experien
NFL Running Back Derrick Henry Joins Amazfit as Athlete Ambassador18.7.2025 16:00:00 EEST | Press release
Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), announced Baltimore Ravens running back Derrick Henry as the newest elite athlete to join its growing roster of ambassadors. Known for his rare combination of speed and strength, Henry will utilize Amazfit wearables to power every phase of his training, recovery and sleep as he prepares for his 10th NFL season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250718322498/en/ Derrick Henry is the newest elite athlete to join Amazfit's growing roster of ambassadors. As one of the most prolific running backs of his generation, Henry has amassed an impressive array of accolades during his career, including NFL Offensive Player of the Year, two rushing titles, and five Pro Bowl selections. With Amazfit as his official smart wearable partner, the former Heisman winner will integrate advanced health and fitness tracking into his training regimen and r
Qualcomm Announces Quarterly Cash Dividend18.7.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on September 25, 2025, to stockholders of record at the close of business on September 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensin
MultiBank Group Confirms $MBG Token Listings on MEXC and Gate.io on TGE Day in Addition to MultiBank.io and Uniswap18.7.2025 15:34:00 EEST | Press release
MultiBank Group, the world’s largest & most regulated financial derivatives institution, is proud to announce that its highly anticipated $MBG Token will be listed on two new major global cryptocurrency exchanges — MEXC and Gate.io — on the day of its official Token Generation Event (TGE), July 22, 2025, in addition to MultiBank.io and Uniswap. The $MBG Token will go live on: MultiBank.ioGate.ioMEXCUniswap This new dual listing will allow millions of users across both exchanges to seamlessly access and trade $MBG using their existing accounts, ensuring immediate market participation at launch. The Token Generation Event (TGE) is now approaching following the successful completion of two pre-sale rounds, where MultiBank Group issued 7 million tokens in Round 1 and 3 million tokens in Round 2 — both of which sold out within minutes. Naser Taher, Chairman and Founder of MultiBank Group said “With $MBG, we’re introducing a utility token built to deliver real-world value, transparency, and
SLB Announces Second-Quarter 2025 Results18.7.2025 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the second-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716727689/en/ The exterior of the SLB headquarters in Houston, Texas. Second-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2025Mar. 31, 2025Jun. 30, 2024SequentialYear-on-yearRevenue $8,546 $8,490 $9,139 1% -6% Income before taxes - GAAP basis $1,285 $1,063 $1,421 21% -10% Income before taxes margin - GAAP basis 15.0% 12.5% 15.5% 251 bps -52 bps Net income attributable to SLB - GAAP basis $1,014 $797 $1,112 27% -9% Diluted EPS - GAAP basis $0.74 $0.58 $0.77 28% -4% Adjusted EBITDA* $2,051 $2,020 $2,288 2% -10% Adjusted EBITDA margin* 24.0% 23.8% 25.0% 21 bps -103 bps Pretax segment operating income* $1,584 $1,556 $1,854 2% -15% Pretax segment operating margin* 18.5% 18.3% 20.3% 20 bps -175 bps Net income attributable to SLB, excluding charges & credits* $1,016
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom